Novo Nordisk Seeks EMA Approval for Semaglutide Dose; Ozempic Shows 25% Weight Loss in Trials; FDA Accepts ET-600 NDA

Recent studies and developments indicate that obesity treatments like semaglutide, marketed under names such as Ozempic, are paving the way for a new era in weight loss care. Novo Nordisk has submitted a new product dose to the European Medicines Agency, with clinical trials showing that one in three participants achieved at least 25% weight loss. Experts highlight that these GLP-1 receptor agonist drugs not only reduce appetite but also help address addictive behaviors related to ultra-processed foods. Former FDA commissioner David Kessler has noted the role of such medications in mitigating food addiction. Meanwhile, the FDA has accepted a New Drug Application for ET-600, an oral desmopressin solution by Eton Pharmaceuticals, with a Prescription Drug User Fee Act (PDUFA) date set for February 25, 2026.